0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
This Month in Archives of Dermatology |

This Month in Archives of Dermatology FREE

[+] Author Affiliations

Section Editor: Robin L. Travers, MD


Arch Dermatol. 2011;147(1):13. doi:10.1001/archdermatol.2010.398.
Text Size: A A A
Published online

DERMOSCOPY OF PATIENTS WITH MULTIPLE NEVI

Much of the economic burden in melanoma screening results from excisions and biopsies of benign lesions, especially in patients with multiple melanocytic nevi. Dermoscopy may reduce the number of unnecessary excisions, although irregular dermoscopic features still prompt unnecessary excisions. In this study, Argenziano et al demonstrate that the comparative approach to dermoscopy (assessment of the nevus in the context of multiple lesions) may dramatically reduce the number of unnecessary excisions compared with the morphologic approach (assessment of a single lesion).

See Article

EVOLUTION OF NEVI DURING TREATMENT WITH NATALIZUMAB

Natalizumab is a humanized monoclonal antibody directed against the cellular adhesion molecule α4 integrin. Natalizumab interrupts inflammatory processes and has been used as monotherapy for highly active relapsing-remitting multiple sclerosis. Four cases of melanoma have been reported in association with natalizumab use. In this cohort study, Castela et al demonstrate the same rate of clinical and dermoscopic changes of nevi under natalizumab therapy compared with the spontaneous evolution of nevi reported in the literature. These data support the absence of malignant transformation of nevi owing to the inhibition of α4 integrin by natalizumab.

See Article

PARANEOPLASTIC PEMPHIGUS HERPETIFORMIS WITH IGG ANTIBODIES TO DESMOGLEIN 3 AND WITHOUT MUCOSAL LESIONS

Pemphigus herpetiformis (PH) is a rare immunobullous disorder with clinical features of dermatitis herpetiformis and immunopathologic features of pemphigus. In most cases, the target antigen is desmoglein 1 (Dsg1), although rare patients manifest anti-Dsg3 autoantibodies. Although the association of cancer with immunobullous disease is well described, PH is only rarely reported in association with a neoplasm. In this case report, Prado et al describe the first patient with PH, an underlying lung neoplasm, and IgG autoantibodies directed against Dsg3 and an unknown 178-kDa protein. It remains unclear if the anti–178-kDa protein autoantibodies were involved with this patient's unusual presentation.

See Article

DEVELOPMENT OF A PHOTOGRAPHIC SCALE FOR CONSISTENCY AND GUIDANCE IN DERMATOLOGIC ASSESSMENT OF FOREARM SUN DAMAGE

The quest for consistent clinical assessment has led to the development of objective grading methods for characterization and quantification of photodamage. To date, no valid and reliable photographic assessment scale of forearm skin sun damage has been developed. McKenzie et al used 96 standardized photographs of forearm skin for grading by an expert dermatologist and 5 community dermatologists using an existing 9-category scale. The expanded Dermatologic Assessment Form Forearm Photographic Assessment scale has great potential to yield highly consistent scoring of forearm sun damage in study participants.

See Article

HISTOPATHOLOGIC STUDY OF HIDRADENITIS SUPPURATIVA FOLLOWING LONG-PULSED 1064-NM ND:YAG LASER TREATMENT

Hidradenitis suppurativa (HS) is a chronic, recurrent, inflammatory disease of the axilla, inframammary, and inguinal areas. Therapies include lifestyle changes, antibiotics, retinoids, and immunosuppressive, biological, and surgical therapies. In this prospective, controlled clinical trial, Xu et al demonstrate that the long-pulsed 1064-nm Nd:YAG laser is a novel and effective treatment option for HS. This laser may penetrate deeply enough for selective photothermolysis of the follicular unit and destruction of organized inflammatory lesions in the dermis, offering a noninvasive, well-tolerated, and effective treatment option for patients with this debilitating disease.

See Article

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

221 Views
0 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs